image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

SEC Filing Details

Document Details

Form
DRS
Filing Date
February 22, 2021
Document Date
February 22, 2021
Form Description
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Filing Group
Registration Statements
Company
Nurix Therapeutics, Inc.
Issuer
NURIX THERAPEUTICS, INC.
Print Page
Email Alerts
RSS Feeds
Contact IR